Immuno-Oncology Overview

  • ID: 3445976
  • Report
  • Region: Global
  • 133 pages
  • Datamonitor Healthcare
1 of 3
CAR-T Cell Therapy Early Clinical Results are Extremely Promising
This is an overview of the field of immuno-oncology and the various immuno-oncology classes. Immuno-oncology is one of the most promising and fastest growing areas of cancer research, as well as one of the most active areas in terms of licensing deals and acquisitions.

Highlights

The PD-1/PD-L1 inhibitor and TCR/CAR-T therapy drug classes lead development of all immuno-oncology drugs. However, several novel mechanisms of action are also in early-phase development.

Developers of approved PD-1/PD-L1 inhibitors - Bristol-Myers Squibb, Merck & Co, Roche, AstraZeneca, and Pfizer - currently dominate the immuno-oncology field in terms of the number of ongoing, conducted, and planned trials.

Furthermore, PD-1/PD-L1 inhibitors remain a focal point of immuno-oncology combinations, with various types of combination approaches being studied.

Methodology

Three key opinion leaders were interviewed for this analysis, with the full interviews being transcribed. A survey of 56 medical oncologists across the US and five major EU markets (France, Germany, Italy, Spain, and the UK) was also conducted. Pipeline data were provided by Biomedtracker and Pharmaprojects, clinical trial data were provided by Trialtrove, and deals information was provided by Strategic Transactions.
Note: Product cover images may vary from those shown
2 of 3
EXECUTIVE SUMMARY

IMMUNO-ONCOLOGY OVERVIEW
Overview of the immune system and tumor cells
Bibliography

CURRENT STATUS OF IMMUNO-ONCOLOGY DEVELOPMENT
Immuno-oncology trials by status
Immuno-oncology trials by phase
Immuno-oncology trials by disease
Immuno-oncology trials by company
Immuno-oncology trials by mechanism of action
Immuno-oncology trials by country

PD-1/PD-L1 INHIBITORS
Class description
Clinical development of PD-1/PD-L1 inhibitors
Deals
­Bibliography

CTLA-4 INHIBITORS
Class description
Clinical development of CTLA-4 inhibitors
Deals
Bibliography

TCR AND CAR-T THERAPIES
Class description
Clinical development of TCR and CAR-T therapies
Deals
Bibliography

IDO INHIBITORS
Class description
Clinical development of IDO inhibitors
Deals
Bibliography

EMERGING DRUG CLASSES
CD40 agonists
CEA inhibitors
CSF1R inhibitors
GITR agonists
LAG3 inhibitors
OX40 agonists
TIGIT inhibitors
TIM3 inhibitors
VISTA inhibitors
Bibliography

BRISTOL-MYERS SQUIBB
Immuno-oncology portfolio
Deals
Bibliography

MERCK & CO
Immuno-oncology portfolio
Deals
Bibliography

ROCHE
Immuno-oncology portfolio
Deals
Bibliography
ASTRAZENECA
Immuno-oncology portfolio
Deals
Bibliography

PFIZER
Immuno-oncology portfolio
Deals
Bibliography

IMMUNO-ONCOLOGY COMBINATIONS

KOL SURVEY

KOL INTERVIEWS
KOL-1: anonymous US medical oncologist/hematologist
KOL-2: anonymous US medical oncologist
KOL-3: Dr David McDermott

List of Figures
Figure 1: Receptors and ligands involved in cell surface-mediated molecular signaling systems that control immune response
Figure 2: Distribution of immuno-oncology trials, by trial status
Figure 3: Phase of planned and ongoing immuno-oncology trials, by trial status
Figure 4: Top 25 cancers/cancer sites included in immuno-oncology trials, segmented by trial phase
Figure 5: Top 25 industry sponsors of immuno-oncology trials, segmented by trial status
Figure 6: Top 25 mechanisms of action in immuno-oncology trials, segmented by trial status
Figure 7: Top 25 countries hosting immuno-oncology trials, segmented by trial status
Figure 8: PD-1 and PD-L1 inhibitors
Figure 9: Top 10 cancers/cancer sites included in clinical trials studying PD-1/PD-L1 inhibitors, segmented by trial status
Figure 10: Top 10 industry sponsors of trials studying PD-1/PD-L1 inhibitors, segmented by trial status
Figure 11: Top 10 cancers/cancer sites included in clinical trials studying CTLA-4 inhibitors, segmented by trial status
Figure 12: Top five industry sponsors of trials studying CTLA-4 inhibitors, segmented by trial status
Figure 13: Overview of Kymriah’s CAR-T technology
Figure 14: Top 10 cancers/cancer sites included in clinical trials studying TCR/CAR-T therapies, segmented by trial status
Figure 15: Top 10 industry sponsors of trials studying TCR/CAR-T therapies, segmented by trial status
Figure 16: Top 10 cancers/cancer sites included in clinical trials studying IDO inhibitors, segmented by trial status
Figure 17: Top five industry sponsors of trials studying IDO inhibitors, segmented by trial status
Figure 18: Top 10 cancers/cancer sites featured in trials sponsored or co-sponsored by Bristol-Myers Squibb, segmented by trial status
Figure 19: Top 10 cancers/cancer sites featured in trials sponsored or co-sponsored by Merck & Co, segmented by trial status
Figure 20: Top 10 cancers/cancer sites featured in trials sponsored or co-sponsored by Roche, segmented by trial status
Figure 21: Top 10 cancers/cancer sites featured in trials sponsored or co-sponsored by AstraZeneca, segmented by trial status
Figure 22: Top 10 cancers/cancer sites featured in trials sponsored or co-sponsored by Pfizer, segmented by trial status
Figure 23: Number of trials testing each immuno-oncology combination approach, segmented by trial status
Figure 24: Number of immuno-oncology combination trials featuring approved PD-1/PD-L1 inhibitors, segmented by combination type

List of Tables
Table 1: Overview of approved and pipeline PD-1/PD-L1 inhibitors
Table 2: Key deals related to PD-1/PD-L1 inhibitors, 2017
Table 3: Overview of approved and pipeline CTLA-4 inhibitors
Table 4: Key deals related to CTLA-4 inhibitors, 2017
Table 5: Overview of approved and pipeline TCR/CAR-T therapies
Table 6: Key deals related to TCR/CAR-T therapies, 2017
Table 7: Overview of pipeline IDO inhibitors
Table 8: Key deals related to IDO inhibitors, 2017
Table 9: Overview of pipeline CD40 agonists
Table 10: Overview of pipeline CEA inhibitors
Table 11: Overview of pipeline CSF1R inhibitors
Table 12: Overview of pipeline GITR agonists
Table 13: Overview of pipeline LAG3 inhibitors
Table 14: Overview of pipeline OX40 agonists
Table 15: Overview of pipeline TIGIT inhibitors
Table 16: Overview of pipeline TIM3 inhibitors
Table 17: Overview of pipeline VISTA inhibitors
Table 18: Overview of Bristol-Myers Squibb’s immuno-oncology portfolio
Table 19: Key deals related to Bristol-Myers Squibb, 2017
Table 20: Overview of Merck & Co’s immuno-oncology portfolio
Table 21: Key deals related to Merck & Co, 2017
Table 22: Overview of Roche’s immuno-oncology portfolio
Table 23: Key deals related to Roche, 2017
Table 24: Overview of AstraZeneca’s immuno-oncology portfolio
Table 25: Key deals related to AstraZeneca, 2017
Table 26: Overview of Pfizer’s immuno-oncology portfolio
Table 27: Key deals related to Pfizer, 2017
Table 28: Medical oncologists included in the author’s immuno-oncology KOL survey, 2017
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll